Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

About this Publication
Title
Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.
Pubmed ID
25664444 (View this publication on the PubMed website)
Publication
Ann. Intern. Med. 2015 Feb; Volume [Epub ahead of print]: Pages [Epub ahead of print]
Authors
Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, Kazerooni E
Abstract

BACKGROUND: Lung cancer screening with low-dose computed tomography (LDCT) has been recommended, based primarily on the results of the NLST (National Lung Screening Trial). The American College of Radiology recently released Lung-RADS, a classification system for LDCT lung cancer screening.

OBJECTIVE: To retrospectively apply the Lung-RADS criteria to the NLST.

DESIGN: Secondary analysis of a group from a randomized trial.

SETTING: 33 U.S. screening centers.

PATIENTS: Participants were randomly assigned to the LDCT group of the NLST, were aged 55 to 74 years, had at least a 30-pack-year history of smoking, and were current smokers or had quit within the past 15 years.

INTERVENTION: 3 annual LDCT lung cancer screenings.

MEASUREMENTS: Lung-RADS classifications for LDCT screenings. Lung-RADS categories 1 to 2 constitute negative screening results, and categories 3 to 4 constitute positive results.

RESULTS: Of 26 722 LDCT group participants, 26 455 received a baseline screening; 48 671 screenings were done after baseline. At baseline, the false-positive result rate (1 minus the specificity rate) for Lung-RADS was 12.8% (95% CI, 12.4% to 13.2%) versus 26.6% (CI, 26.1% to 27.1%) for the NLST; after baseline, the false-positive result rate was 5.3% (CI, 5.1% to 5.5%) for Lung-RADS versus 21.8% (CI, 21.4% to 22.2%) for the NLST. Baseline sensitivity was 84.9% (CI, 80.8% to 89.0%) for Lung-RADS versus 93.5% (CI, 90.7% to 96.3%) for the NLST, and sensitivity after baseline was 78.6% (CI, 74.6% to 82.6%) for Lung-RADS versus 93.8% (CI, 91.4% to 96.1%) for the NLST.

LIMITATION: Lung-RADS criteria were applied retrospectively.

CONCLUSION: Lung-RADS may substantially reduce the false-positive result rate; however, sensitivity is also decreased. The effect of using Lung-RADS criteria in clinical practice must be carefully studied.

PRIMARY FUNDING SOURCE: National Institutes of Health.

Related CDAS Studies
Related CDAS Projects